News

RFK Jr.’s mRNA hostility could hurt more than just vaccines

The Nobel Prize-winning technology underpinning COVID-19 vaccines is also fueling a host of biotechs developing treatments ...

Traws Pharma, Inc.: Traws Pharma Reports Second Quarter 2025 Results and Business Highlights

Advancing novel programs for respiratory viruses that pose pandemic threats or risk of serious illness, including SARS CoV2 (ratutrelvir) and influenza (Tivoxavir marboxil, TXM) Prioritization of ratu ...

Infectious Disease Therapies Market Projected to Reach $101 Billion by End of 2030

According to the latest study from BCC Research, "Global Markets for Infectious Disease Treatments" is expected to grow from ...
The Manila Times2d

Traws Pharma Reports Second Quarter 2025 Results and Business Highlights

Advancing novel programs for respiratory viruses that pose pandemic threats or risk of serious illness, including SARS CoV2 ...
BioWorld5d

New PB2 inhibitors disclosed in Innovstone Therapeutics patent

Innovstone Therapeutics Ltd. has divulged prodrugs of deuterated baloxavir marboxil derivatives acting as polymerase basic protein 2 (PB2) (influenza virus) inhibitors reported to be useful for the ...
Devdiscourse5d

Health Sector Highlights: Activism, Market Surges, and Emergency Responses

Engine Capital urges Avantor board changes; China's Ab&B Bio-Tech shares soar; French chlorine factory fire prompts alert; IO ...
Zacks Investment Research on MSN5d

Merck Stock Down 4% Since Q2 Results: How to Play the Stock

Merck MRK stock has declined 4% since it announced second-quarter results on July 29 before market open. While the company’s ...